Clinical Trial Update: A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update shows results for trastuzumab deruxtecan (Enhertu) in solid tumors with HER2 activating mutations; the study is currently not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Gastric Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Urothelial Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-15